Active	Status	Sponsor type	Region	Phase	Filter
9 Active 7 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grabowski, Marcin
IMPROVE-MC, NCT04654988 / 2020-003877-23: Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.	Recruiting	4	100	Europe	Prednisone, Azathioprine, Placebo Prednisone, Placebo Azathioprine	Medical University of Warsaw, Medical Research Agency	Myocarditis, Heart Failure, Endomyocardial Biopsy, Cardiomyopathies, Secondary, Immunosuppression	09/27	03/28
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)	02/29	02/29
PROLONG-ANG3, NCT05256654: A Study of LY3561774 in Participants With Mixed Dyslipidemia	Completed	2	204	Europe, Canada, Japan, US, RoW	LY3561774, Placebo	Eli Lilly and Company	Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia	03/24	05/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	Active, not recruiting	2	456	Europe, Canada, Japan, US, RoW	LY3540378, Placebo	Eli Lilly and Company	Heart Failure, Heart Failure With Preserved Ejection Fraction	01/25	01/25
NCT05086523: Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study	Recruiting	1/2	28	Europe, RoW	Programmable Hypertension Control (BackBeat Moderato), Pacing (BackBeat Moderato)	BackBeat Medical Inc	Hypertension,Essential, Systolic Hypertension	08/23	09/23
afterAMI, NCT04793425: Mobile App and Digital System for Patients After Myocardial Infarction	Recruiting	N/A	100	Europe	Mobile application (afterAMI)	Medical University of Warsaw	mHealth, Telemedicine	12/22	07/23
NCT05719454: Novel Setup Algorithm for Cardiac Neuromodulation Therapy	Recruiting	N/A	30	Europe, RoW	CNT testing	BackBeat Medical Inc	Hypertension, Bradycardia	07/24	10/24
MYO-PL, NCT04827706: Occurrence, Trends, Management and Outcomes of Patients Hospitalized With Myocarditis	Active, not recruiting	N/A	19978	Europe		Medical University of Warsaw	Myocarditis, Sudden Cardiac Death, Cardiomyopathies, Arrythmia, Heart Failure	12/21	12/21